Calidi Biotherapeutics (CLDI) Misses Q1 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St climbs as oil slips; SpaceX spectrum deal weighs on telecoms
- Oil falls as Trump comments on Iran talks ease supply concerns
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts CLDI Hot Sheet
Join SI Premium – FREE
Calidi Biotherapeutics (NYSE: CLDI) reported Q1 EPS of ($0.18).
For earnings history and earnings-related data on Calidi Biotherapeutics (CLDI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX's spectrum deal puts SIRI's satellite assets in focus
- SpaceX (SPCX) call put ratio 2 calls to 1 put with a focus on expiring October 9 weekly calls
- UnitedHealth Group (UNH) call put ratio 1.1 calls to 1 put into quarter results
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
